This core has two main functions: a) to help evaluate the materials that are intended for clinical studies, in a number of model systems, using the advanced animal imaging instrumentation available at the COH; and b) the analysis of clinical blood, urine, bone marrow, and tissue biopsy samples. The Specific Functions are: 1) To provide the needed facilities and expertise for evaluating the biodistribution and imaging cells and antibody constructs in small animals, and 2) To perform core studies on clinical samples obtained from patients entered on imaging and therapy trials. This Core is a critical component. All antibody and T-cell constructs will be evaluated in vitro and in vivo prior to translation into the clinic. The in vivo analysis will be performed as part of this Core using the expertise of the Core's personnel. Animal biodistribution and imaging studies will be performed using the Core personnel with help as needed from the individual projects. Luciferase transfected tumor cell lines and T-cells will be generated as part of the projects and antibodies and their engineered constructs will be radiolabeled as part of the individual projects. The in vivo studies will be performed in the City of Hope Animal Resource Center in the Parvin building. The City of Hope National Medical Center and Beckman Research institute is developing an animal imaging facility. It has a Xenogen in vivo biophotonic imaging system (IVIS) and has recently accepted delivery of a Biospace Instruments animal gamma scintillation camera. A Concorde Microsystems microPET@/ R4 for small animals imaging has been ordered; it is due to be delivered in June 2003. This core will also analyze clinical samples from patients participating in the clinical trials. Analysis of blood and urine samples to determine the pharmacodynamics of the radiolabeled antibodies and their engineered constructs will be performed by this Core. Samples will be counted to determine the pharmacokinetics and selected samples will be analyzed by high performance liquid chromatography to evaluate the status of the labeled construct. In vitro assays to determine circulating levels of infused antibodies and constructs, as well as their immunogenicity, will also be performed by this Core.. Immunoassays will be performed by ELISA or using methods developed using the PerkinEImer VICTOR plate reader using time-resolved fluorometry.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-G (J1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
City of Hope/Beckman Research Institute
United States
Zip Code
Herrera, Alex F; Rodig, Scott J; Song, Joo Y et al. (2018) Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow Transplant 24:514-520
Budde, Lihua E; Wu, David; Martin, Daniel B et al. (2018) Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial. Br J Haematol 183:601-607
Herrera, A F; Palmer, J; Martin, P et al. (2018) Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Ann Oncol 29:724-730
Zhao, Xingli; Zhang, Zhuoran; Moreira, Dayson et al. (2018) B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors. Mol Ther 26:695-707
Adamus, Tomasz; Kortylewski, Marcin (2018) The revival of CpG oligonucleotide-based cancer immunotherapies. Contemp Oncol (Pozn) 22:56-60
Herrera, Alex F; Moskowitz, Alison J; Bartlett, Nancy L et al. (2018) Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood 131:1183-1194
Chen, Robert W; Palmer, Joycelynne M; Tomassetti, Sarah et al. (2018) Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation. J Hematol Oncol 11:87
Wang, Xiuli; Walter, Miriam; Urak, Ryan et al. (2018) Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma. Clin Cancer Res 24:106-119
Herrmann, Andreas; Lahtz, Christoph; Nagao, Toshikage et al. (2017) CTLA4 Promotes Tyk2-STAT3-Dependent B-cell Oncogenicity. Cancer Res 77:5118-5128
Urak, Ryan; Walter, Miriam; Lim, Laura et al. (2017) Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy. J Immunother Cancer 5:26

Showing the most recent 10 out of 97 publications